larsensliders (2)
larsensliders (3)
previous arrow
next arrow

Welcome To

Larsen Formulations Pvt Ltd

Larsen Formulations is a therapy focused healthcare company providing novel solutions in the management of Chronic Respiratory Diseases (CRDs). Chronic respiratory diseases are diseases of the airways and other structures of the lung. Some of the most common are chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases and pulmonary hypertension. Risk factors include air pollution, tobacco smoke, occupational chemicals and dusts exposure, and frequent lower respiratory infections during childhood. CRDs are not curable, however, various forms of treatment that help dilate major air passages and improve shortness of breath can help control symptoms and increase the quality of life for people who are suffering with these diseases.

The aim of Larsen Formulations is to support doctors in their efforts to reduce the toll of morbidity, disability and premature mortality related to chronic respiratory diseases, and specifically, asthma and chronic obstructive pulmonary disease by offering novel therapeutic solutions and quality medication at affordable price.

Global Facts on CRDs

Million People
201

suffer from asthma, a common disease among children.

Million People
220

suffer from chronic obstructive pulmonary disease (COPD). From 1990 to 2015, the global prevalence of COPD increased by 44.2%.

Million People
2

die each year from COPD, an estimated 6% of all deaths worldwide.

of COPD
80 %

deaths occur in low-income and middle-income countries.

INDIAN Facts on CRDs

The contribution of chronic respiratory diseases to the total DALYs (Disability Adjusted Life Years, The sum of years of potential life lost due to premature, mortality and the years of productive life lost due to disability) in India increased from 4•5% (95% UI 4•0–4•9) in 1990 to 6•4% (5•8–7•0) in 2016. Of the total global DALYs due to chronic respiratory diseases in 2016, 32•0% occurred in India. COPD and asthma were responsible for 75•6% and 20•0% of the chronic respiratory disease DALYs, respectively, in India in 2016. The number of cases of COPD in India increased from 28•1 million (27•0–29•2) in 1990 to 55•3 million (53•1–57•6) in 2016, an increase in prevalence from 3•3% (3•1–3•4) to 4•2% (4•0–4•4). There were 37•9 million (35•7–40•2) cases of asthma in India in 2016. India also leads the world in deaths due to Asthma with 43% of global asthma deaths occurring in our country. Yet awareness in the healthcare community and the public remains low about these two chronic lung conditions which cause a huge health and economic burden on our health and health care system. Changes in environment, urbanization, pollution, Change in dietary habits and lifestyles have contributed to rapid increase in allergies. The incidence of allergy is said to have doubled during the past 20 years. It is estimated that 1 out of 3 people are allergic to something and in a survey by All India Co-ordinated Project on Aeroallergens and human health, New Delhi, 2000, showed that 20–30 % of the population suffers from allergic rhinitis and that 15 % develop asthma.

Our Core Values

Quality

Expertise

Integrity

Compliance

Our Products

Contact Us

+91 8297 22 333 4

contact@larsenformulations.com

: Registered office :
A-302, Tasai Darshan, Shree Malang road near Nandiwali Talav, Kalyan east, Thane Mumbai ,Thane, MH 421306.

Copyright © Larsen Formulations Pvt Ltd All Rights Reserved.

Design And Developed by Maheswara Web Tech

Call Now Button